Department of Radiology, Seoul Metropolitan Government Seoul National University, Boramae Medical Center, Seoul, Republic of Korea.
Eur J Radiol. 2012 Aug;81(8):1751-7. doi: 10.1016/j.ejrad.2011.03.044. Epub 2011 Apr 7.
The purpose of this study was to evaluate the enhancement pattern and the diagnostic accuracy of gadofluorine M in comparison with gadopentetate dimeglumine in a rabbit VX2 tumor model.
Thirteen rabbits with experimentally induced VX2 carcinomas in the thighs underwent sequential T1-weighted enhancement MR imaging using a 3.0T MR imager, first with gadopentetate dimeglumine, and then 24 (n=4) or 4h (n=9) later with gadofluorine M. In 4 rabbits with 13 tumors, the time-percentage enhancement (PE; i.e., percentage of signal intensity increase) curve was obtained for up to 24h for each contrast agent. In 9 rabbits with 49 tumors (random numbers of VX2 tumors were inoculated at random sites in the thigh), 3 readers unaware of the histopathologic results interpreted the MR images and determined the number and conspicuity level of the detected tumors. The reference standard was the histopathology of the specimen.
The time-to-peak PE for gadopentetate dimeglumine was 1min and gadopentetate dimeglumine showed a rapid washout pattern. The time-to-peak PE for gadofluorine M was 30min and gadofluorine M showed a plateau enhancement pattern for up to 24h. The peak PE of gadofluorine M was approximately twice that of the same dose of gadopentetate dimeglumine (108.2±14.8 vs. 51.5±24.0). The sensitivities for detecting VX2 tumors by 3 readers were 89.8% (44/49), 85.7% (42/49), and 95.9% (47/49) for gadopentetate dimeglumine-enhanced MR imaging, and 87.8% (43/49), 89.8% (44/49), and 89.8% (44/49) for gadofluorine M-enhanced MR imaging. No significant differences in the sensitivities existed between the two contrast agents for any reader. However, the conspicuity level of tumors was superior with gadofluorine M-enhanced MR imaging for two readers and similar for the other reader.
Gadofluorine M showed strong and plateau enhancement of tumors for up to 24h. In the reader study, gadofluorine M showed better conspicuity for VX2 tumors than gadopentetate dimeglumine, but had a similar sensitivity.
本研究旨在评估氟代钆喷酸葡胺（gadofluorine M）与钆喷葡胺（gadopentetate dimeglumine）在兔 VX2 肿瘤模型中的增强模式和诊断准确性。
13 只大腿部有 VX2 癌的实验性兔接受了 3.0T MR 成像仪的 T1 加权增强磁共振成像（MR），首先使用钆喷葡胺，然后在 24 小时（n=4）或 4 小时（n=9）后使用氟代钆喷酸葡胺。在 4 只兔子的 13 个肿瘤中，每个对比剂的时间-百分比增强（PE；即信号强度增加的百分比）曲线在 24 小时内获得。在 9 只兔子的 49 个肿瘤中（大腿的随机部位接种了不同数量的 VX2 肿瘤），3 名对病理结果不知情的读者对 MR 图像进行了判读，并确定了检测到的肿瘤的数量和显著性水平。参考标准是标本的组织病理学。
钆喷葡胺的达峰时间 PE 为 1 分钟，且钆喷葡胺呈快速洗脱模式。氟代钆喷酸葡胺的达峰时间 PE 为 30 分钟，氟代钆喷酸葡胺呈 24 小时平台增强模式。氟代钆喷酸葡胺的峰值 PE 约为相同剂量的钆喷葡胺的两倍（108.2±14.8 比 51.5±24.0）。3 名读者检测 VX2 肿瘤的灵敏度分别为 89.8%（44/49）、85.7%（42/49）和 95.9%（47/49），钆喷葡胺增强磁共振成像；87.8%（43/49）、89.8%（44/49）和 89.8%（44/49），氟代钆喷酸葡胺增强磁共振成像。任何一位读者使用两种对比剂的灵敏度均无显著差异。然而，对于两位读者，氟代钆喷酸葡胺增强磁共振成像的肿瘤显著性水平更高，而对于另一位读者，两种对比剂的肿瘤显著性水平相似。
氟代钆喷酸葡胺显示肿瘤增强程度强且呈平台期达 24 小时。在读者研究中，氟代钆喷酸葡胺显示出比钆喷葡胺更好的 VX2 肿瘤显著性，但灵敏度相似。
